### REFERENCES

### THAI

- สุนันท์ พงษ์สามารถ และคณะ. 2529. รายงานการวิจัยเรื่อง การประเมินทางชีวเคมีและทาง ชีวภาพของคุณค่าทางโภชนาการของเห็ด (Biochemical and biological evaluation of nutrition quality of mushrooms). ภาควิชาชีวเคมี คณะเภลัชศาสตร์ จุฬาลงกรณ์ มหาวิทยาลัย
- กองโภชนาการ กรมอนามัย กระทรวงสาธารณสุข. 2530. ตารางแสดงคุณค่าอาหารไทยในส่วนที่ กินได้ 100 กรัม (Nutritive values of Thai foods. โรงพิมพ์ทหารผ่านศึก. กรุงเทพ

### **ENGLISH**

- Abraham, S.K. and Graf, U. 1996. Protection by coffee against somatic genotoxicity in *Drosophila*: role of bioactivation capacity. *Food Chem Toxicol* 34: 1-14
- Abraham, S.K., Singh, S.P. and Kesavan, P.C. 1998. In vivo antigenotoxic effects of dietary agents and beverages co-administered with urethane: assessment of the role of glutathione S-transferase activity. *Mutat Res* 413: 103-10
- Baars, A.J. 1980. Biotransformation of xenobiotics in *Drosophila melanogaster* and its elevance for mutagenicity testing. *Drug Metab Rev* 11: 191-221
- Banik, S., and Nandi, R. 2004. Effect of supplementation of rice straw with biogas residual slurry manure on the yield, protein and mineral contents of oyster mushroom. *Ind. Crops and Products* 20, 311-19
- Becker, H.J. 1966.Genetic and variegation mosaics in the eye of *Drosophila*. Curr *Topics Develop Biol* 1: 155-71
- Benzie, I.F.F, Wu, I, and Buswell, J.A.1998. Antioxidant activities of mushrooms and mushroom products. Abstracts of the Second International Conference on Natural Antioxidants and Anticarcinogens in Nutrition, Health and Disease, Helsinki, Finland; Abstract No. WI/3, cited in Shi, Y.L., Benzei, I.F.F., and Buswell J.A. 2002. Role of tyrosinase in the genoprotective effect of the edible mushroom, Agaricus bisporus; *LifeSciences* 70: 1595-1608

- Berenblum, I. 1982. Sequencial aspects of chemical carcinogenesis: skin. In: Becker FF, editor. Cancer Volume 1. 2<sup>nd</sup> ed. New York: Plenum Press 415-84
- Bobek, P., Ozdi'n, L., and Galbavy', S. 1998. Dose- and Time-Dependent Hypocholesterolemic Effect of Oyster Mushroom (Pleurotus ostreatus) in Rats. *Nutrition* 282-6
- Bruneton J. 1995. Pharmacognosy, phytochemistry, medicinal plants. Hatton CK, translator. Paris: lavoisier Publishers, Translation of: Pharmacognosie, cited in Craig, W.J. 1999. Health- promoting properties of common herbs. *Am J Clin Nutr*, 491s-9s
- Buckenhuskes, H.J., 1997. Fermented Vegetables. In: Doyle, M.P., concerns regarding recombinant DNA technology, Beuchat, L.R., Montville, T.J. (Eds.), Food Microbiology: Fundamentals and Frontiers, ASM Press, Washington D.C, pp. 595–609, cited in Caplice, E., and Fitzgereld, G.F. 1999. Food fermentations: role of microorganisms in food production and preservation. *Int J Food Microbiol* 50: 131-49
- Caplice, E., and Fitzgereld, G.F. 1999. Food fermentations: role of microorganisms in food production and preservation. *Int J Food Microbiol* 50: 131-49
- Carlson, G.P. 1994. The effect of inducers and inhibitors of urethane metabolism on its *in vitro* and *in vivo* metabolism in rats. *Cancer Lett* 87: 145-50
- Carragay, A.B. 1992. Cancer-preventative foods and ingredients. Food technol 46:65-8
- Chan, M.M. and Fong, D. Anti-inflammation and cancer-preventive Immunomodulation through diet: effects of curcumin On T-lymphocytes. In: Huang MT, Osawa T, Ho CT, Rosen RT, eds. 1994. Food phytochemicals for cancer prevention. II. Teas, spices and herbs. Washington, DC: American Chemical Society 222-30
- Chang, R. 1996. Functional properties of edible mushrooms. Nutr Rev 54: S91-93
- Chang, ST. 1999. World production of cultivated edible and medicinal mushrooms in 1997 with emphasis on Lentinus edodes (Berk.) Sing. in China. *Inter J Med Mushrooms* 1: 291–300
- Chang, S.T., and Buswell, J.A. 1996. Mushroom nutriceuticals. *World J Microb Biotech* 12:473–6

- Cheung, L.M., Peter, C.K., and Ooi, V. 2003. Antioxidant activity and total phenolics of edible mushroom extracts. *Food Chem* 249-55
- Chihara, G., Hamuro, J., Maeda, Y.Y., Arai, Y., Fukuoka, F., 1970. Fractionation and purification of the polysacchrides with marked antitumor activity, especially Lentinan, from *Lentinus edodes*. *Cancer Res* 30: 2776-81
- Chihara, G., Maeda, Y., Hamuro, J., Saski, T., and Fukuoka, F. 1969. Inhibition of mouse sarcoma 180 by polysaccharides from *Letinula edodes* (Berk.) Sing, Nature 222 (1969) 687–688, cited in Lima, PL., *et al*, 2001. *Lentinus edodes* (Berk.) Pegler (Shiitake) modulates genotoxic and mutagenic effects induced by alkylating agents in vivo. *Mutat Res* 496, 23-32
- Cohen, G. 1985. Oxidative stress in the nervous system. In: Sies H, editor. Oxidative Stress. London: Academic press; 383–401, cited in Shi, Y.L., Benzei, I.F.F., and Buswell J.A. 2002. Role of tyrosinase in the genoprotective effect of the edible mushroom, Agaricus bisporus; *LifeSciences* 70: 1595-1608
- Condon, S., 1987. Responses of lactic acid bacteria to oxygen. *FEMS Microbiol Rev*. 46, 269–280, cited in Caplice, E., and Fitzgereld, G.F. 1999. Food fermentations: role of microorganisms in food production and preservation. *Int J Food Microbiol* 50: 131-49
- Cook, N.C.and Samman, S. 1996. Flavonoids- chemistry, metabolism, cardioprotective effects, and dietary sources. *J Nutr Biochem* 7: 66-76
- Cragg, G.M., Schepanz, S.A., Suffness, M., Grever, M.R. 1993. The taxol supply crisis.

  New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. *J Nat Prod* 56:1657-68
- Craig, W.J. 1999. Health-promoting properties of common herbs. *Am J Clin Nutr* 491s-9s
- Cuvelier, M.E., Berset, C. and Richard, H. 1994. Antioxidant constituents in sage (Saliva officinalis). *J Agric Food Chem* 42: 665-9
- Dahl, G.A., Miller, J.A., and Miller, E.C. 1978. Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. *Cancer Res* 38: 3793-804
- Dauusch, J.G., Nixon, S.W. 1990. Gartic: a review of its relationship to malignant disease. *Prev Med* 19:346-61

- De Flora, S., Astengo, M., Serra, D., and Bennicelli, C. 1986. Inhibition of urethane-induced lung tumors in mice by dietary N-acetylcysteine. *Cancer Lett* 32: 235-41
- Dennis, J.J., Howath, N., Key, P.E., Pointer, M., and Massey, R.C. 1989. Investigation of ethyl carbamate levels in some fermented foods and alcoholic beverages. Food Addit Contam 3: 383-9
- Dreosti, I.E. 1996. Bioactive ingredients: antioxidants and polyphenols in tea. *NutrRev* 54:S51-8.
- Field, K.J. and Lang, C.M. 1988. Hazards of Urethane (ethyl carbamate): a review of the literature. *Lab Anim* 22: 255-62
- Frei, H. and Wurgler, F.E. 1988. Statistical methods to decide whether mutagenicity test data from *Drosophila* assays indicate a positive, negative, or inconclusive result. *Mutat Res* 203: 297-308.
- Frolich, A. and Wurgler, F.E. 1989. New tester strains with improved bioactivation capacity for the *Drosophila* wing-spot test. *Mutat Res* 216: 179-87
- Frolich, A. and Wurgler, F.E. 1990a. *Drosophila* wing-spot test: improved detectability of genotoxicity of polycyclic aromatic hydrocarbons. *Mutat Res* 234: 71-80
- Frolich, A. and Wurgler, F.E. 1990b. Genotoxicity of ethyl carbamate in the *Drosophila* wing spot test: dependence on genotype-controlled metabolic capacity. *Mutat Res* 244: 201-8
- Frolich, A. and Wurgler, F.E. 1991. The "High Bioactivation" cross for the SMART assay with the wing. Drosophila *Inf Serv* 70: 246-7
- Fuhraman, B. et al. 1997. Licorice extract and its major polyphenol glabridin protect low- density lipoprotein against lipid peroxidation: in vitro and ex in vivo studies in humans and in atherosclerotic apolipoprotein E- deficients mice. *Am J Clin Nutr* 66: 267-75
- Gerritsen, Y.A.M., Chapelon, C.G.J. and Wichers, H.J. 1994. The low-isoelectric point tyrosinase of *Agaricus bisporus* may be a glycoprotein. *Phytochemistry* 35:573–7, cited in Shi, Y.L., Benzei, I.F.F., and Buswell J.A. 2002. Role of tyrosinase in the genoprotective effect of the edible mushroom, Agaricus bisporus; *LifeSciences* 70: 1595-1608

- Graf, U., Frei, H., Kagi, A., Katz, A.J., and Wurgler, F.E. 1989. Thirty compounds tested in the *Drosophila* wing spot test. *Mutat Res* 222: 359-73
- Graf, U., and Van, S.N. 1992. Improved high bioactivation cross for the wing somatic mutation and recombination test in *Drosophila melanogaster*. *Mutat Res* 271: 59-67
- Graf, U., Wurgler, F.E., Katz, A.J., Frei, H., Juon, H., and Hall, C.B. 1984. Somatic mutation and recombination test in *Drosophila melanogaster*. *Environ Mutagen* 6: 153-88
- Graham, D.G. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. *Molecular Pharmacol* 14:633–43, cited in Shi, Y.L., Benzei, I.F.F., and Buswell J.A. 2002. Role of tyrosinase in the genoprotective effect of the edible mushroom, Agaricus bisporus; *LifeSciences* 70: 1595-1608
- Greenwald, P., Clifford, C.K., and Milner, J.A. 2001. Diet and cancer prevention. *Eur J Cancer* 37(8): 948-65
- Gruter, A., Friederich, U., and Wurgler, F.E. 1990. Antimutagenic effects of mushrooms. *Mutat Res* 231: 243- 9
- Gruter, A., Friederich, U., and Wurgler, F.E. 1991. The mutagenicity of edible mushrooms in a histidine- independent bacterial test system. *Food Chem Toxicol* 29: 159-65.
- Guengerich, F.P., and Kim, D.H. 1991. Enzymatic oxidation of ethyl carbamate and its role as an intermediate in the formation of 1,N°-ethenoadenosine. *Chem Res Toxicol* 4: 413-21
- Guengerich, F.P., Kim, D.H., and Iwasaki, M. 1991. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. *Chem Res Toxicol* 4: 168-79
- Hallstrom, I., Blanck, A., and Atuma, S. 1984. Genetic variation in cytochrome P-450 and xenobiotic metabolism in *Drosophila melanogaster*. *Biochem Pharmacol* 33: 13-20
- Hatvani, N. 2001. Antibacterial effect of the culture fluid of *Lentinus edodes* mycelium grown in submerged liquid culture. *Inter J Antimicrob Agents* 71–4

- Hirasawa, M., Shouji, N., Neta, T., Fukushima, K., and Takada, K. 1999. Three kinds of antibacterial substances from *Lentinus edodes* (Berk.) Sing. (Shiitake, an edible mushroom). *Inter J Antimicrob Agents* 151–7
- Hirata, S., Odajima, T., Kohama, G., Ishigaki, S., Niitsu, Y. 1992. Significance of glutathione S- transferase as a tumor marker in patients with oral cancer. *Cancer*, 70: 2381-87 cited in Kamada, K et al. 2004. Nuclear glutathione S-transferase prevents apoptosis by reducing the oxidative stress- induced formation of exocyclic DNA products. *Free Radical Biology & Med* 37:1875-84
- Hollman, P.C.H. 1997. Bioavailability of flavonoids. Eur J Clin Nutr 51: s66-9
- Ismail, A., Marjan, Z.M., and Foong, C.W. 2004. Total antioxidant activity and phenolic content in selected vegetables. *Food Chem* 87: 581–6
- Jakoby, W. 1978. A group of multifunctional detoxification proteins. *Adv Enzymol Relat Areas Mol Biol* 46: 383-414 cited in Kamada, K et al. 2004. Nuclear glutathione S- transferase ¶ prevents apoptosis by reducing the oxidative stress- induced formation of exocyclic dna products. *Free Rad Biol & Med* 37:1875-84
- Kada, T. and Ishidate, M. 1980. Environmental Mutagens Data Book No1. Tokyo: Scientists
- Karekar, V., Joshi, S., and Shinde, S.L. 2000. Antimutagenic profile of three antioxidants in the Ames assay and the *Drosophila* wing spot test. *Mutat Res* 468(2): 183-94
- Katz, A.J. 1989. Sodium thiosulfate inhibits cisplatin-induced mutagenesis in somatic tissue of *Drosophila*. *Environ Mol Mutagen* 13: 97-9
- Kawakishi, S. and Tanigawa, M. 1997. Antioxidative protein in Japanese mushroom. In: Hiramatsu M, Yoshikawa T, Inoue M, editors. Food and Free Radicals. New York: Plenum Press; 67–73, cited in Shi, Y.L., Benzei, I.F.F., and Buswell J.A. 2002. Role of tyrosinase in the genoprotective effect of the edible mushroom, *Agaricus bisporus*; *Life Sciences* 70: 1595-1608

- Kemper, R.A., Myers, S.R., and Hurst, H.E. 1995. Detoxification of vinyl carbamate epoxide by glutathione: evidence or participation of glutathione- S- transferases in metabolism of ethinyl carbamate. *Toxicol Appl Pharmacol* 135: 110-8
- Kim, H.S., Kacew, S., and Lee, B.M. 1999. In vitro chemopreventive effects of plant polysaccharides (*Aloe barbadensis Miller*, *Lentinus edodes*, *Ganoderma lucidum* and *Coriolus versicolor*. *Carcinogensis* 20: 1637-40
- Kim, M., Hagiwara, N., Smith, S.J., Yamamoto, T., Yamane, T. and Takahashi, T. 1994.

  Preventive effect of green tea polyphenols on colon carcinogenesis. In: Huang

  MT, Osawa T, Ho CT, Rosen RT, eds. Food phytochemicals for cancer prevention

  II. Teas, spices and herbs. Washington, DC: American Chemical Society: 51-5
- Kurata, N., Hurst, H.E., Kemper, R.A., and Waddell, W.J. 1991. Studies on induction of metabolism of ethyl carbamate in mice by ethanol. *Drug Metab Dispos* 19: 239-40
- Ladanyi, A., Timar, J. and Lapis, K. 1993. Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. *Cancer Immunol Immunother* 36:123-6
- Lau, B.H.S., Tadi, P.P., Tosk, J.M. 1990. *Allium sativum* (garlic) and cancer prevention. *Nutr Res* 10: 937-48.
- Lau, B.H.S., Woolley, J.L., Marsh, C.L., Barker, G.R., Koobs, D.H., Torrey, R.R. 1986.

  Superiority of intralesional immuno- therapy with *Corynebacterium parvum* and *Allium sativum* on control of murine transitional cell carcinoma. *J Urol* 136: 701-5
- Lee, C.H. 1997. Lactic acid fermented foods and their benefits in Asia. *Food control* 8: 259-69
- Lee, C. H., Adler-Nissen, J. and Barwald, G. (1994) Lactic Acid Fermentation of Non-daily Food and Beverages. Harn Lim Won, Seoul, cited to Lee, C.H. 1997. Lactic acid fermented foods and their benefits in Asia. Food control 8: 259-69
- Lea, M.A., Xiao, Q., Sadhukhan, A.K., Coule, S., Wang, Z.Y and Yang, C.S. 1993. Inhibitory effects of tea extracts and (-)-epigallocalechin gallate on DNA synthesis and proliferation of hepatoma and erylhroleukemia cells. *Cancer Lett* 68:231-6
- Leithauser, M.T., Liem, A., Stewart, B.C., Miller, E.C., and Miller, J.A. 1990. 1, Note then oadenosine formation, mutagenicity and murine tumor induction as indicators of the generation of an electrophilic epoxide metabolite of the closely

- Nagabhushan, M. and Bhide, S.V. 1992. Curcumin as an inhibitor of cancer. *J Am Coil*Nutr 1:192-8
- NCI. 1978. Survey of compounds which have been tested for carcinogenic activity. US Department of Health and Human services. Washiton: US Government Printing Office. NIH Publication No. 80- 453
- NCI. 1979- 80. Survey of compounds which have been tested for carcinogenic activity.

  US Department of Health and Human services. Washiton: US Government

  Printing Office. NIH Publication No. 84- 2688
- Negishi, T., Arimoto, S., Nishizaki, C., and Hayatsu, H. 1989. Inhibitory effect of chlorophyll on the genotoxicity of 3-amino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2). *Carcinogenesis* 10: 145-9
- Negishi, T., Nakano, H., Kitamura, A., Itome, C., Shiotani, T., and Hayatsu, H. 1994.

  Inhibitory activity of chlorophyllin on the genotoxicity of carcinogens in

  Drosophila. Cancer Lett 83: 157-64
- Nigsch, J. 1978. DDT-resistanz und nitrosamin-empfindlichkeit genetisch verschiedener stamme von *Drosophila melanogaster*[Article in French] [Ph.D. thesis]. Swiss Federal Institute of Technology, Zurich
- Oh, Y.J., Hwang, I.J. and Leitzmann, C.1994. Nutritional and physiological evaluation of kimchi. In *The Science of Kimchi*, 226-45. Korean Society of Food Science and Technology, Seoul, cited in Lee, C.H. 1997. Lactic acid fermented foods and their benefits in Asia. *Food control* 8: 259-69
- Oliveira, M., Jordao, B.Q., Ribeiro, L.R., da Eira, A.F., and Mantovani, M.S. 2002. Antigenotoxic effect of aqueous extracts of sun mushroom (*Agaricus blazei* Murill lineage 99/26) in mammalian cells in vitro. *Food Chem Toxicol* 40: 1775-80
- Olvera,O., Zimmering, S., Arceo, C., and Cruces, M. 1993. The protective effects of chlorophyllin in treatment with chromium (VI) oxide in somatic cells of *Drosophila*. *Mutat Res* 30: 201-4
- Olvera,O., Zimmering, S., Arceo, C., Guzman, J., and de la Rosa, M.E. 1995. Evidence for the protective effect of ascorbic acid (Vitamin C) in treatment with gamma-rays and chromium (VI) oxide (CrO3) in somatic cells of *Drosophila*.

  Mutat Res 346: 19-21

- Ooi, V.E. and Liu, F., 2000. Immunomodulation and anti- cancer activity of polysaccharide- protein complexes. *Current Med Chem* 77: 715-29
- Padmajaprasad, V., Kaladhar, M., and Ramesh, V. 1997. Thermal isomerisation of Noxalyl-L-α, **p**-Gdiaminopropionic acid, the neurotoxin in *Lathyrus sativus*, during cooking. *Food Chem*, Vol. 59, *No.* 1, pp. 77-80
- Papaparaskeva, C., Ioannides, C., and Walker, R. 1991. Agaritine dose not mediate the mutagenicity of the edible mushroom *Agaricus bisporus*. *Mutagenesis* 6: 213-7
- Park, K.K., Liem, A., Stewart, B.C., and Miller, J.A. 1993. Vinyl carbamate epoxide, a major strong electrophilic, mutagenic and carcinogenic metabolite of vinyl carbamate and ethyl carbamate (urethane). *Carcinogenesis* 14: 441-50
- Pilegaard, K., Kristiansen, E., Meyer, O.A, and Gry, J. 1997. Failure of the cultivated mushroom (*Agaricus bisporus*) to induce tumors in the A/J mouse lung tumor model. *Cancer Lett* 120: 79-85
- Ratcliffe, B., Flurkey, W.H., Kuglin, J., and Dawley, R. 1994. Tyrosinase, laccase, and peroxidase in mushrooms (Agaricus, Crimini Oyster and Shiitake). *J Food Science* 59:824–7
- Rehman, Z.U., Islam, M., and Shah, W.H. 2003. Effect of microwave and conventional cooking on insoluble dietary fibre components of vegetables. *Food Chem* 80: 237–40
- Roberts, D.B. 1986. Basic *Drosophila* care and techniques. In: Roberts DB, editor. *Drosophila*: a practical approach. Oxford: ORL Press: 1-38
- Ross, A.E., Nagel, D.L., and Toth, B. 1982. Occurrence. Stability and decomposition of β- N- [γ-L-(+)- glutamyl]-4- hydroxymethyl- phenylhydrazine (agaritine) from the mushroom Agaricus bisporus. *Food Chem Toxicol* 20: 903- 7
- Sanchez, I., Palop, L. and Ballesteros C. 2000. Biochemical characterization of lactic acid bacteria isolated from spontaneous fermentation of 'Almagro' eggplants.

  Inter J Food Microb 59: 9–17
- Schlatter, J. and Lutz, W.K. 1990. The carcinogenic potential of ethyl carbamate (urethane): risk assessment at human dietary exposure levels. *Food Chem Toxicol* 28: 205-11



## APPENDIX A

### Preparation of Standard Culture Medium

## Ingredient

1.	Corn flour	125	g
2.	Sugar	100	g
3.	Yeast	50	g
4.	Agar	14	g
5.	Proprionic acid	5	ml
6.	Water	1000	ml

## Steps of preparations of standard medium for Drosophila melanogaster stocks.

- 1. Boil and blend sugar, agar, yeast and corn flour in 1000 ml water until sticky.
- 2. Add propionic acid.
- 3. Fill each 125 ml-erlenmeyer flask with 50 ml of the medium.
- 4. Close the flask with a plug (made of gauze and cotton cover with aluminum foil).
- 5. Sterile the flasks containing medium in an autoclave at 120 °C for 15 min to avoid microbial contamination that can harm the flies.

### APPENDIX B

Statistical Consideration (Frei and Wurgler, 1988)

In experiments designed to assess the mutagenicity of a chemical, most often a treatment series were compared with a control series. One might like to decide whether the compound used in the treatment should be considered as mutagenic or non-mutagenic. The formulation of 2 alternative hypotheses allowed one to distinguish among the possibilities of a positive, inconclusive, or negative result of an experiment (Selby and Olson, 1981).

In the null hypothesis one assumes that there was no difference in the mutation frequency between control and treated series. Rejection of the null hypothesis indicated that the treatment resulted in a statistically increased mutation frequency. The alternative hypothesis postulated a priory that the treatment results in an increased mutation frequency compared to the spontaneous frequency. The alternative hypothesis was rejected if the mutation frequency was significantly lower than the postulated increased frequency. Rejection indicates that the treatment did not produce the increase requires to consider the treatment as mutagenic. If neither of the 2 hypotheses was rejected, the results were considered inconclusive as one could not accept at the same time the 2 mutually exclusive hypotheses. In the practical application of the decision procedure, one defines a specific alternative hypothesis requiring the mutation frequency in the treated series be m times that in the control series and used together with the null hypothesis. It might happen in this case that both hypotheses had to be rejected. This should mean that the treatment was weakly mutagenic, but led to a mutation frequency which was significantly lower than m times the control frequency.

Testing against the null hypothesis ( $H_0$ ) at the level  $\alpha$  and against the alternative a hypothesis ( $H_A$ ) at the level  $\beta$  led to the error probabilities for each of the possible diagnoses: positive, weakly but positive, negative, or inconclusive. The following four decisions were possible; 1) accept both hypotheses; these can not be true simultaneously, so no conclusions can be drawn--inconclusive result; 2) accept the first hypothesis and reject the second hypothesis--negative result; 3) reject the first

hypothesis and accept the second hypothesis--positive result; 4) reject both hypotheses --weak effect.

### Calculation step by step

### Estimation of spot frequencies and confidence limits of m<sub>e</sub>

Particularly in the case that both hypotheses,  $H_0$  as well as  $H_A$ , had to be rejected, one might be interested in knowing the confidence interval of  $m_e$ , i.e., of the estimated multiple by which the mutation frequency in the experimental series was larger than the spontaneous frequency. The estimated value was

$$m_e = (n_t/n) N_c$$

$$(n_c/n) N_t$$

where  $N_c$  and  $N_t$  represented the respective sample sizes in control and treatment series,  $n_c$  and  $n_t$  the respective numbers of mutations found, and n the total of mutations in both series together. Exact lower and upper confidence limits  $p_1$  and  $p_u$  for the proportion  $n_c/n$  on one hand, as well as  $q_1$  and  $q_u$  for the proportion  $n_t/n$  on the other hand, may be determined according to Sachs (Sach, 1982 and 1984). He gave an easy method to calculate these values using an F-distribution table. To determined  $q_1$  and  $p_0$  one-sidedly at the level  $q_1$  and  $q_2$  and  $q_3$  and  $q_4$  and  $q_5$  also one-sidedly at the level  $q_5$ . In this way and in agreement with the foregoing section, a confidence limit  $q_5$  1 led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  and  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while a confidence limit  $q_5$  m led to rejection of  $q_5$  while  $q_5$  m led to rejection of  $q_5$  m led to

In the first step, F-distribution according to Sachs (Sach, 1982 and 1984) were used to determine the value  $F_{\nu_1,\nu_2}$  at the level  $\alpha=0.05$ , where the degrees of freedom (V1, V2) were given by the equations

$$V_1 = 2 (n - nt + 1) \text{ and } V_2 = 2n$$

In the second step, the F-value so obtained was used to calculate the lower confidence limit  $(q_1)$  for the proportion of spots in the experimental series

$$q_1 = n_t / [n_t + (n-n_t + 1 F_{v_1, v_2}]$$

This gave a lower confidence limit for the frequency of spots per wing in the control which was equal to

$$f_{t,1} = q_1 n/N_t$$

This was the following complementarity, namely that the lower confidence limit for the number of spots in the experimental series  $(q_1n)$  plus the upper confidence limit for the number of spots in the experiment  $(p_un)$  was equal to the total number of spots (n) found in experimental and control series together, i.e.,

$$P_{n} = (1-q_{1}) n$$

This gave an upper limit for the frequency of spots per wing for the control which is

$$f_{\rm cu} = q_{\rm u} n/N_{\rm c}$$

The lower confidence limit m<sub>1</sub> of the multiple m<sub>e</sub> was determined as the ratio between the lower confidence limit for the frequency in the treated series and the upper confidence limit for the frequency in the control, i.e.,

$$m_1 = \underline{f}_{t,\underline{t}} = \underline{q}_{\underline{t}} \underline{n/N}_t$$

$$f_{c,\underline{u}} \qquad p_{\underline{u}} \underline{n/N}_c$$

Only in the case that m1, the lower confidence limit of me, was larger than 1.0 would reject  $H_0$ . Since this was not the case,  $H_0$  remain accepted.

In the same way, the lower confidence limit of the spot frequency may be determined in the control  $f_{c_i}$ , which will give  $f_{t_i}$ , the upper confidence limit of the spot frequency in the experimental series. This is also done one-sidedly, at the level  $\beta$  = 0.05. The inverse ratio of these values will provide the upper 5% confidence limit  $m_u$  for the multiple  $m_e$ .

Again, the F-distrivution according to Sachs (Sach, 1984 ) was used and determined the value  $F_{v1,\ v2}$  at the level  $\beta$  = 0.05, where the degrees of freedom ( $_{v1}\ _{v2}$ ) were this time given by the equations

$$V1 = 2(n-n_c + 1)$$
 and  $V2 = 2 n_c$ 

The F-value so obtained was used to calculate the lower confidence limit (p1) for the proportion of spots in the control

$$P_1 = n_c / [n_c + (n - n_c + 1) F_{v_1, v_2}]$$

This gave a lower confidence limit for the frequency of spots per wing in the control which equal to

$$f_{c,1} = p_1 n / N_c$$

Again, There was complementarity, in that the lower confidence limit for the number of spots in the control (p1n) plus the upper confidence limit for the number of spots in the experiment (q\_n) was equal to the total number of spots (n), so that

$$q_{11}n = (1-p_1)n$$

This gave an upper limit for the frequency of spots per wing for this series which is

$$f_{t,u} = q_u n/N_t$$

The upper confidence limit  $m_u$  of the multiple  $m_e$  can be determined as the ratio between the upper confidence limit for the frequency in the treated series and the lower confidence limit for the frequency in the control, i.e.,

$$m_{u} = \underline{f}_{\underline{t},\underline{u}} = \underline{q}_{\underline{u}} \underline{n/N}_{\underline{t}}$$

$$f_{\underline{c},1} \quad p_{1} \underline{n/N}_{\underline{c}}$$

 $H_A$  was rejected if  $m_u$ , the upper confidence limit of  $m_e$ , was less than m (m=2 for the total of all spots and for the small single spots, and m=5 for the large single spots as well as for the twin spots). Substitution of  $m_e$  by  $m_1$  or  $m_u$  in the above formulas provided the respective exact upper and lower confidence limits for the frequencies estimated.

## **BIOGRAPHY**

NAME

Miss Umaporn Suweeraporn

DATE OF BIRTH

11 September 1977

PLACE OF BIRTH

Ubonrachathani, Thailand

**INSTITUTIONS ATTENDED** 

Khon Kaen University, 1995-1999

Bachelor of Science in Pharmacy

Chulalongkorn University, 2002-2005

Master of Science in Pharmacy Program in Food

Chemistry and Medicinal Nutrition

**ADDRESS** 

682/23 Citypark Soi. Pattanakarn 38, Pattanakarn

Road, Suanleung Bangkok. 10250